These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 22833573)

  • 41. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
    McEllin B; Camacho CV; Mukherjee B; Hahm B; Tomimatsu N; Bachoo RM; Burma S
    Cancer Res; 2010 Jul; 70(13):5457-64. PubMed ID: 20530668
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment.
    Pan MR; Hsieh HJ; Dai H; Hung WC; Li K; Peng G; Lin SY
    J Biol Chem; 2012 Feb; 287(9):6764-72. PubMed ID: 22219182
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PARP inhibitors: its role in treatment of cancer.
    Chen A
    Chin J Cancer; 2011 Jul; 30(7):463-71. PubMed ID: 21718592
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
    Jacquemont C; Taniguchi T
    Cancer Res; 2007 Aug; 67(15):7395-405. PubMed ID: 17671210
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells.
    Connell CM; Shibata A; Tookman LA; Archibald KM; Flak MB; Pirlo KJ; Lockley M; Wheatley SP; McNeish IA
    J Clin Invest; 2011 Apr; 121(4):1283-97. PubMed ID: 21383502
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
    Williamson CT; Muzik H; Turhan AG; Zamò A; O'Connor MJ; Bebb DG; Lees-Miller SP
    Mol Cancer Ther; 2010 Feb; 9(2):347-57. PubMed ID: 20124459
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents.
    Haince JF; Kozlov S; Dawson VL; Dawson TM; Hendzel MJ; Lavin MF; Poirier GG
    J Biol Chem; 2007 Jun; 282(22):16441-53. PubMed ID: 17428792
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ABT-888 and quinacrine induced apoptosis in metastatic breast cancer stem cells by inhibiting base excision repair via adenomatous polyposis coli.
    Siddharth S; Nayak D; Nayak A; Das S; Kundu CN
    DNA Repair (Amst); 2016 Sep; 45():44-55. PubMed ID: 27334689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Opposing effects of the UV lesion repair protein XPA and UV bypass polymerase eta on ATR checkpoint signaling.
    Bomgarden RD; Lupardus PJ; Soni DV; Yee MC; Ford JM; Cimprich KA
    EMBO J; 2006 Jun; 25(11):2605-14. PubMed ID: 16675950
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting the DNA damage response in oncology: past, present and future perspectives.
    Basu B; Yap TA; Molife LR; de Bono JS
    Curr Opin Oncol; 2012 May; 24(3):316-24. PubMed ID: 22476188
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer.
    Meyer F; Becker S; Classen S; Parplys AC; Mansour WY; Riepen B; Timm S; Ruebe C; Jasin M; Wikman H; Petersen C; Rothkamm K; Borgmann K
    Cells; 2020 Jan; 9(1):. PubMed ID: 31963582
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genistein induces G2/M cell cycle arrest and apoptosis of human ovarian cancer cells via activation of DNA damage checkpoint pathways.
    Ouyang G; Yao L; Ruan K; Song G; Mao Y; Bao S
    Cell Biol Int; 2009 Dec; 33(12):1237-44. PubMed ID: 19732843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
    Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
    J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells.
    Ray S; Shyam S; Fraizer GC; Almasan A
    Mol Cancer Ther; 2007 Apr; 6(4):1368-78. PubMed ID: 17431115
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
    Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
    PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.
    Muñoz-Gámez JA; López Viota J; Barrientos A; Carazo Á; Sanjuán-Nuñez L; Quiles-Perez R; Muñoz-de-Rueda P; Delgado Á; Ruiz-Extremera Á; Salmerón J
    Liver Int; 2015 Apr; 35(4):1430-41. PubMed ID: 24821649
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
    Ivy SP; Kunos CA; Arnaldez FI; Kohn EC
    Expert Opin Investig Drugs; 2019 Sep; 28(9):771-785. PubMed ID: 31449760
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.